CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neximmune Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neximmune Inc
9119 Gaither Road
Phone: (301) 825-9810p:301 825-9810 GAITHERSBURG, MD  20878  United States Ticker: NEXINEXI

Business Summary
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company’s T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. It is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Sol J.Barer 75 11/1/2019 11/1/2019
President, Chief Executive Officer, Director KristiJones 59 2/15/2022 3/1/2018
Principal Financial and Accounting Officer TimothyStover 9/2/2023 9/2/2023
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 50 (As of 12/31/2022)
Outstanding Shares: 1,302,521 (As of 2/6/2024)
Shareholders: 67
Stock Exchange: NASD
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024